

Roche fact sheet

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience.

Roche is also the world leader in *in vitro* diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.

Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs (over 9 billion US dollars) in R&D and posted sales of 46.8 billion Swiss francs (50.5 billion US dollars).

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Roche's capabilities are augmented by technology collaborations and a constellation of worldwide alliances to help develop individual products and entire product portfolios.

Roche has one of the strongest drug development pipelines in the industry with over 25 phase III projects and multiple projects currently in registration. The pipeline overall comprises over 60 new potential medicines and over 30 additional indications for existing medicines. Half of the projects in late-stage development utilize a companion diagnostic test and thus could help advance personalized healthcare.

Roche is recognized as a leader in Corporate Governance and Sustainability. Roche is listed on the FTSE4 Good Indices and is the 2013 Super Sector leader for healthcare in the Dow Jones Sustainability Indices (DJSI). Roche participates in various humanitarian and educational projects.

Pharma


Pharma is made up of Roche Pharma represented in over 150 countries, Genentech (the Group's US pharma business) and a majority shareholding of Chugai in Japan. Seven of Roche's 10 top-selling medicines are manufactured using biotechnology, and biopharmaceuticals account for more than 70% of pharmaceutical sales.

Global sales of top 10 medicines in 2013	CHF billion	USD billion ¹
MabThera/Rituxan ^{2,3}	7.0	7.5
Avastin ²	6.3	6.7
Herceptin ²	6.1	6.6
Lucentis ⁴	1.7	1.8
Xeloda ²	1.5	1.6
Tarceva ²	1.3	1.4
Pegasys ⁵	1.3	1.4
Actemra/RoActemra ³	1.0	1.1
CellCept ³	0.9	0.9
Xolair ³	0.8	0.9


Diagnostics

Diagnostics is the world leader in *in vitro* diagnostics; products used to test blood and other body fluids and tissue samples to obtain information for the diagnosis, treatment and monitoring of diseases. Its product portfolio ranges from blood glucose meters for people with diabetes and point-of-care testing devices for use in doctors' offices, to high-throughput analysers for hospitals and commercial diagnostic laboratories. The division also supplies state of the art instruments and reagents for life science research.


The Roche innovation network




Sales by therapeutic area 2013




Sales by region 2013



Sales by business area 2013



Sales by region 2013



Italics = growth rates as measured at constant exchange rates

¹ Exchange rate used CHF/USD: 0.93 (2013)

² Oncology


³ Immunology

⁴ Ophthalmology

⁵ Infectious diseases

Key financials


As reported in Swiss Francs (CHF)



Translated to US dollars (USD)¹



Per security data as reported in Swiss Francs (CHF)



Translated to U.S. dollars (USD)¹



¹ Exchange rates used CHF/USD: 0.93 (2013); 0.94 (2012); 0.89 (2011)

² Exchange rate as determined by the depository bank during the dividend payment and tax reclaim process

Contact information

Investor Relations North America

Roche Holdings, Inc.

Genentech, Inc.

1 DNA Way

South San Francisco CA 94080

Phone: +1 650 225 5566

Fax: +1 650 225 8326

Email: rocheirna@gene.com

www.roche.com/investors

Primary contacts for non-institutional investors:

Stacy Galvin

Senior Specialist

Email: galvin.stacy@gene.com

Nina Goworek

IR Officer

Email: goworek.nina@gene.com

Additional information

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

Information accessed herein may not under any circumstances be used for the purpose of, or in connection with, the quotation of any securities on an automated inter-dealer quotation system within the meaning of Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Copyright © 18 April 2014 by Roche Investor Relations North America, South San Francisco.

Security information

Roche's ADR (American Depositary Receipt) is on OTCQX International Premier under the symbol RHHBY. Traded in US dollars, eight (8) ADRs represent one (1) underlying non-voting equity security (Genussschein, abbreviated NES). Roche's non-voting equity security and the Roche voting share are both listed on SIX Swiss Exchange.

Symbol	Security	No. of securities	Trading/Listing	CUSIP/ISIN
RHHBY	US security (ADR)	Note a)	OTCQX	771195104
ROG	Non-voting equity security (NES)	702,562,700	SIX Swiss Exchange	CH0012032048
RO	Voting share	160,000,000	SIX Swiss Exchange	CH0012032113

Note a) The number of ADRs in issue varies depending on demand and conversion in and out of the underlying non-voting equity security (NES)

The Roche ADR facility was initiated in 1992 when one (1) ADR represented one hundredth (1/100) of one underlying non-voting equity security. The current ADR ratio is a result of several splits and ratio changes.

ADR splits and ratio changes

Record date	Effective date	ADR split	ADR to NES ratio
20 Feb 2014	27 Feb 2014	2 for 1	8 to 1
05 Jan 2009	09 Jan 2009	2 for 1	4 to 1
21 Jan 2005	25 Jan 2005	2 for 1	2 to 1
Note b)	04 May 2001	1 for 1	1 to 1
Prior to 04 May 2001	-	-	1 to 1/100

Note b) On 3 April 2001, the Board of Directors approved a 100 for 1 split of the non-voting equity security. This was followed by an opposite 1 for 100 change in the ADR to non-voting equity security ratio. As a result, no new ADRs were distributed.

ADR 5-year dividend history

Declared date ^c	Ex-dividend date ^d	Record date ^e	Pay date for ADR	Gross dividend (USD)	Net dividend ^f (USD)
04 Mar 2014	06 Mar 2014	10 Mar 2014	22 Apr 2014	1.11	0.92
05 Mar 2013	07 Mar 2013	11 Mar 2013	11 Apr 2013	0.97	0.81
06 Mar 2012	08 Mar 2012	12 Mar 2012	12 Apr 2012	0.92	0.77
02 Mar 2011	03 Mar 2011	07 Mar 2011	25 Apr 2011	0.88	0.74
02 Mar 2010	04 Mar 2010	08 Mar 2010	20 Apr 2010	0.70	0.58

Note c) Declared date is the date of approval of the proposed dividend at the Annual General Meeting

Note d) Ex-dividend date is the first date where trading takes place without dividend

Note e) Record date is the last date on which the security must be held in custody in order to be eligible to receive dividend (as settlement typically takes place trading day + 3 days)

Note f) Dividends are subject to Swiss withholding tax of 35% at the time of initial payment. For ADR holders, the depository bank performs a tax reclaim process with the Swiss tax authorities. The actual dividend tax paid depends on the specific tax status of the dividend recipient. For the amount listed in the net dividend column, a 15% tax rate has been assumed plus a dividend, reclaim and payment fee of \$0.0275 per ADR. The tax reclaim process causes a difference in timing between the record date and the ADR pay date. Roche is considered a qualified foreign corporation for US tax purposes. For further tax questions, please consult a tax advisor

Dividend reinvestment program

In 2010, Roche initiated a dividend reinvestment program through the depository bank, J.P. Morgan Chase, to all registered ADR holders. Through the plan, Roche ADR holders can arrange to reinvest all or part of their dividend in the purchase of additional ADRs. For more information, please see the brochure at the Learn more about section of http://www.roche.com/investors/share_information/adr-information.htm.

Other relevant information

In 2006, to facilitate the expanded market access and secondary trading, the Roche ADR obtained a securities manual listing by Standard & Poor's Standard Corporation Records.

Information about buying and selling the Roche ADR as well as information about dividend payments should be addressed to your bank of broker.

ADR depository bank

J.P. Morgan Chase sponsors and administers the Roche ADR facility. The J.P. Morgan ADR shareholder services can be contacted as follows:

Toll free number: 1 800 990 1135
Hearing impaired: 1 866 700 1652

Outside the US: +1 651 453 2128
Email: jpmorgan.adr@wellsfargo.com

Regular correspondence:

J.P. Morgan Chase & Co.
PO. Box 64504
St. Paul MN 55164-0504

Delivery of ADR certificates and overnight mail:

J.P. Morgan Chase & Co.
161 N Concord Exchange
South St. Paul MN 55075